TY - JOUR
T1 - The risk of cytotoxic drugs during pregnancy
AU - Ramsey-Goldman, R.
PY - 1998
Y1 - 1998
N2 - Treatment is frequently required before, during, and after pregnancy in women with rheumatic diseases. It is essential that maternal disease be well controlled to ensure the best possible outcome for mother and child. The physician has multiple responsibilities to monitor not only the interactions between the underlying maternal disease and the outcome of pregnancy, but also the impact of the medications on both patients. The limited experience with cytotoxic medications prior to or during pregnancy in women with rheumatic diseases will be addressed in this article.
AB - Treatment is frequently required before, during, and after pregnancy in women with rheumatic diseases. It is essential that maternal disease be well controlled to ensure the best possible outcome for mother and child. The physician has multiple responsibilities to monitor not only the interactions between the underlying maternal disease and the outcome of pregnancy, but also the impact of the medications on both patients. The limited experience with cytotoxic medications prior to or during pregnancy in women with rheumatic diseases will be addressed in this article.
UR - http://www.scopus.com/inward/record.url?scp=0031718693&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031718693&partnerID=8YFLogxK
U2 - 10.1080/03009742.1998.11720788
DO - 10.1080/03009742.1998.11720788
M3 - Article
C2 - 9759152
AN - SCOPUS:0031718693
SN - 0301-3847
VL - 27
SP - 133
EP - 135
JO - Scandinavian Journal of Rheumatology, Supplement
JF - Scandinavian Journal of Rheumatology, Supplement
IS - 107
ER -